Retatrutide Side Effects: What Phase 3 Trials Reported

Retatrutide side effects in Phase 3 were mostly gastrointestinal, plus a skin sensation called dysesthesia. Here are the trial rates by dose and what remains unknown.

Signal IQ Editorial5 min read · Updated Nov 8, 2026
Retatrutide Side Effects: What Phase 3 Trials Reported
In this article
  1. What are the most common retatrutide side effects?
  2. Retatrutide nausea and other digestive effects
  3. Retatrutide skin sensitivity (dysesthesia)
  4. How long do retatrutide side effects last?
  5. Retatrutide heart rate and blood pressure
  6. Does retatrutide cause tiredness or low mood?
  7. Why unverified vials carry a separate risk
  8. Related reading
  9. Frequently asked questions
  10. References

If you are asking about retatrutide side effects, the Phase 3 answer is mainly digestive upset. A skin symptom called dysesthesia also stood out. Eli Lilly, the sponsor, files it under “burning skin sensation and related” events. It appeared more often as the dose went up, and was usually mild or moderate.

Key takeaways
  • Retatrutide is investigational and not FDA approved. Every number here is taken from Lilly’s published TRIUMPH results.
  • In TRIUMPH-1, between roughly 29% and 42% of retatrutide recipients reported nausea; 15% of the placebo group did.
  • Reports of dysesthesia spanned about 4% to 21% across the four trials, against about 1% with placebo.
  • Participants moved up in dose gradually, so rapid-escalation anecdotes online are not a fair comparison.
  • Vials of unknown origin carry risks that trial results say nothing about.

What are the most common retatrutide side effects?

Stomach and bowel symptoms topped the list. TRIUMPH-1 followed 2,339 adults living with overweight or obesity, without diabetes, across 80 weeks. All participants began at 2 mg and increased every four weeks until reaching their assigned level. The 4, 9 and 12 mg levels are what the trial tested, not advice.

Reported rates, listed at 4 mg, 9 mg and 12 mg, then placebo:

  • Nausea: 28.6%, 38.4%, 42.4%; placebo 14.8%
  • Diarrhea: 25.2%, 34.1%, 32.0%; placebo 13.5%
  • Constipation: 23.8%, 25.9%, 26.1%; placebo 10.9%
  • Vomiting: 10.6%, 22.8%, 25.3%; placebo 4.8%
  • Dysesthesia: 5.1%, 12.3%, 12.5%; placebo 0.9%
  • Urinary tract infection: 7.5%, 8.8%, 8.4%; placebo 5.3%
  • Treatment stopped because of side effects: 4.1%, 6.9%, 11.3%; placebo 4.9%

Retatrutide nausea and other digestive effects

These symptoms tend to bunch up early or right after a step up in dose. Within TRIUMPH-1, digestive problems were the leading reason people left treatment: between 2.2% and 4.6% of retatrutide recipients, compared with 1.2% on placebo.

A clinician will usually want to know when symptoms began relative to a dose change, whether fluids are keeping up (repeated vomiting or diarrhea can dehydrate and strain the kidneys), and whether any abdominal pain is severe or will not settle. Approved drugs in this class carry warnings for pancreatitis and gallbladder disease, so intense or lasting abdominal pain needs urgent assessment.

Retatrutide skin sensitivity (dysesthesia)

The word describes touch that feels wrong: burning, tingling, prickling or tender skin with no clear trigger. Lilly’s summary of all four completed Phase 3 studies (rounded) is below, given as placebo, 4 mg, 9 mg, 12 mg.

  • TRIUMPH-1 (obesity, no diabetes): 1%, 5%, 12%, 13%
  • TRIUMPH-2 (obesity with type 2 diabetes): 1%, 4%, 6%, 7%
  • TRIUMPH-3 (obesity with heart disease): 1%, not studied, 6%, 6%
  • TRIUMPH-4 (obesity with knee osteoarthritis): 1%, not studied, 9%, 21%

The pattern tracked with dose. Severity was mostly mild to moderate. For TRIUMPH-1, Lilly stated that the majority of episodes cleared while treatment continued and that most people stayed on the drug. For TRIUMPH-4, it said the symptom rarely caused anyone to stop, even though roughly one in five people at 12 mg experienced it. How it arises, and how long a single episode lasts, has not been published.

Note: Anyone who notices burning or tingling should jot down the start date, the body location and the duration for their clinician. Fresh numbness, weakness or a symptom that is spreading calls for prompt medical care.

How long do retatrutide side effects last?

There is no published typical duration. Digestive effects clustered around early weeks and escalation steps, and Lilly reported that most dysesthesia events resolved on treatment. Because individual timelines are undocumented, a simple symptom diary is the most useful thing to bring to an appointment.

Retatrutide heart rate and blood pressure

Signal IQ’s retatrutide research page notes that resting heart rate climbs in step with dose, and that research protocols suggest reassessing if it runs 8 to 10 bpm above a person’s baseline. Blood pressure moved the other way in trial reporting. Low blood pressure, including on standing, was reported by 2.7%, 5.3% and 8.8% of participants at 4, 9 and 12 mg versus 0.9% on placebo; Lilly observed it more often in people who already took blood pressure medicine. Reactions at the injection site were seen in 5.5%, 8.9% and 12.2%, against 3.8% with placebo.

Does retatrutide cause tiredness or low mood?

Lilly’s topline summaries do not place tiredness or mood change among the frequent adverse events, and the trial material reviewed gives no numbers for either. Forum reports are anecdotes, and could stem from eating very little, poor sleep, dehydration or a product of unknown content. Ongoing low mood or loss of interest in usual activities merits a clinician’s attention.

Why unverified vials carry a separate risk

All figures above describe Lilly’s own manufactured drug at known doses. In September 2026, Australia’s TGA analysed a vial marketed as retatrutide after a patient was hospitalised with a torn oesophagus caused by relentless vomiting. The vial held no retatrutide at all; it contained semaglutide that was not declared on the label, at about eight times the concentration found in approved semaglutide products. FDA has stated that federal law does not permit compounding retatrutide. See reading a certificate of analysis and is retatrutide FDA approved.

Continue with how retatrutide works, retatrutide vs tirzepatide and peptide side effects, or put questions to Pulse.

Frequently asked questions

What are the most common retatrutide side effects?

Digestive symptoms: nausea, diarrhea, constipation and vomiting. TRIUMPH-1 found nausea in 28.6% to 42.4% of retatrutide users by dose, and 14.8% on placebo.

What is retatrutide dysesthesia?

A strange skin feeling, such as burning, that Lilly classes as “burning skin sensation and related” events. Across the TRIUMPH trials about 5% to 21% of retatrutide participants reported it, depending on dose and group.

How long does retatrutide dysesthesia last?

Lilly says most cases settled during treatment, but it has not released how long a typical episode runs.

Does retatrutide make you tired?

Tiredness is not among the frequent events in Lilly’s topline releases. Feeling worn out is common during any large calorie reduction, so persistent fatigue is worth mentioning to a clinician.

Is it safe to buy retatrutide online?

No. It is investigational and unapproved anywhere, and regulators have identified vials sold under its name that held a different drug.

References

  1. Lilly: TRIUMPH-1 pivotal Phase 3 obesity trial results, May 21, 2026 — lilly.com
  2. Lilly Medical: dysesthesia in the retatrutide TRIUMPH trials — lilly.com
  3. Lilly: TRIUMPH-2 and TRIUMPH-3 results and Q1 2027 submission plan, July 23, 2026 — lilly.com
  4. Lilly: TRIUMPH-4 results, Dec 11, 2025 — lilly.com
  5. TGA: counterfeit retatrutide product testing — tga.gov.au
  6. FDA: concerns with unapproved GLP-1 drugs — fda.gov

Go deeper on Signal IQ

Dosing & protocolRetatrutide

Still have questions? Ask Pulse, Signal IQ’s free AI research assistant, or compare doses in the Peptide Dosage Chart.

Ask Pulse

Educational content only. Nothing here is medical advice or a recommendation to use any compound. Many peptides discussed are research compounds not approved for human use. Talk to a qualified clinician about your situation. Signal IQ does not sell peptides.

Keep reading